382 related articles for article (PubMed ID: 28944534)
41. Combination Ipilimumab and Nivolumab for Metastatic Melanoma Associated With Ciliochoroidal Effusion and Exudative Retinal Detachment.
Tsui E; Madu A; Belinsky I; Yannuzzi LA; Freund KB; Modi YS
JAMA Ophthalmol; 2017 Dec; 135(12):1455-1457. PubMed ID: 29145556
[No Abstract] [Full Text] [Related]
42. Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor.
Kwon CW; Land AS; Smoller BR; Scott G; Beck LA; Mercurio MG
J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e349-e350. PubMed ID: 28129461
[No Abstract] [Full Text] [Related]
43. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
[TBL] [Abstract][Full Text] [Related]
44. Dyshidrosiform pemphigoid due to nivolumab therapy.
Hayashi W; Yamada K; Kumagai K; Kono M
Eur J Dermatol; 2021 Jun; 31(3):411-412. PubMed ID: 34309527
[No Abstract] [Full Text] [Related]
45. Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma.
Adler NR; Murray WK; Brady B; McCormack C; Pan Y
Clin Exp Dermatol; 2018 Jun; 43(4):497-499. PubMed ID: 29396853
[No Abstract] [Full Text] [Related]
46. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
[TBL] [Abstract][Full Text] [Related]
47. Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma.
Amber KT; Valdebran M; Lu Y; De Feraudy S; Linden KG
J Dtsch Dermatol Ges; 2018 Feb; 16(2):196-198. PubMed ID: 29389067
[No Abstract] [Full Text] [Related]
48. Chronic inflammatory demyelinating polyradiculoneuropathy secondary to immune checkpoint inhibitors in melanoma patients.
Patel AS; Snook RJ; Sehdev A
Discov Med; 2019 Aug; 28(152):107-111. PubMed ID: 31926582
[TBL] [Abstract][Full Text] [Related]
49. Cardiotoxicity associated with immune checkpoint inhibitors in cutaneous oncology.
Tabata MM; Choi S; Hirotsu K; Kwong B; Soleymani T
J Am Acad Dermatol; 2020 Apr; 82(4):986-994. PubMed ID: 31437546
[No Abstract] [Full Text] [Related]
50. Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature.
Anastasopoulou A; Papaxoinis G; Diamantopoulos P; Christofidou E; Benopoulou O; Stratigos A; Gogas H
J Immunother; 2018 Apr; 41(3):164-167. PubMed ID: 29309291
[TBL] [Abstract][Full Text] [Related]
51. Bullous pemphigoid developing upon immune checkpoint inhibition with nivolumab.
Grän F; Goebeler M; Gesierich A
Eur J Dermatol; 2019 Aug; 29(4):448-449. PubMed ID: 31625927
[No Abstract] [Full Text] [Related]
52. Diplopia and Acute Vision Loss After Nivolumab Plus Ipilimumab Therapy.
Tambe A; Basnet A; Tambe V; Badrinath M; Mandru R
Am J Ther; 2020 Sep; 28(2):e246-e247. PubMed ID: 33687029
[No Abstract] [Full Text] [Related]
53. Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma.
Mencel J; Gargett T; Karanth N; Pokorny A; Brown MP; Charakidis M
Asia Pac J Clin Oncol; 2019 Dec; 15(6):383-386. PubMed ID: 31373116
[TBL] [Abstract][Full Text] [Related]
54. Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.
Tsiogka A; Jansky GL; Bauer JW; Koelblinger P
Melanoma Res; 2017 Oct; 27(5):524-525. PubMed ID: 28858175
[No Abstract] [Full Text] [Related]
55. Radiation recall dermatitis associated with nivolumab for metastatic malignant melanoma.
Korman AM; Tyler KH; Kaffenberger BH
Int J Dermatol; 2017 Apr; 56(4):e75-e77. PubMed ID: 28102540
[No Abstract] [Full Text] [Related]
56. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).
Nathan P; Ascierto PA; Haanen J; Espinosa E; Demidov L; Garbe C; Guida M; Lorigan P; Chiarion-Sileni V; Gogas H; Maio M; Fierro MT; Hoeller C; Terheyden P; Gutzmer R; Guren TK; Bafaloukos D; Rutkowski P; Plummer R; Waterston A; Kaatz M; Mandala M; Marquez-Rodas I; Muñoz-Couselo E; Dummer R; Grigoryeva E; Young TC; Schadendorf D
Eur J Cancer; 2019 Sep; 119():168-178. PubMed ID: 31445199
[TBL] [Abstract][Full Text] [Related]
57. Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab in a patient with advanced malignant melanoma.
Wada N; Uchi H; Furue M
J Dermatol; 2017 Aug; 44(8):e196-e197. PubMed ID: 28391613
[No Abstract] [Full Text] [Related]
58. Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient.
Fujimura T; Kambayashi Y; Furudate S; Kakizaki A; Hidaka T; Haga T; Hashimoto A; Morimoto R; Aiba S
J Dermatol; 2017 Mar; 44(3):e13-e14. PubMed ID: 27440178
[No Abstract] [Full Text] [Related]
59. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report.
Yonezaki K; Kobayashi T; Imachi H; Yoshimoto T; Kikuchi F; Fukunaga K; Sato S; Ibata T; Yamaji N; Lyu J; Dong T; Murao K
J Med Case Rep; 2018 Jun; 12(1):171. PubMed ID: 29914537
[TBL] [Abstract][Full Text] [Related]
60. Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.
Fukumoto T; Horita N
Eur J Cancer; 2021 Apr; 147():140-141. PubMed ID: 33662688
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
